Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. increased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 501.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 112,055 shares of the specialty pharmaceutical company’s stock after buying an additional 93,422 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.19% of Jazz Pharmaceuticals worth $13,800,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Avantax Advisory Services Inc. acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $264,000. Great Lakes Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the 4th quarter worth $4,488,000. EverSource Wealth Advisors LLC increased its stake in Jazz Pharmaceuticals by 96.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 305 shares during the period. HighTower Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 27.0% in the 4th quarter. HighTower Advisors LLC now owns 9,648 shares of the specialty pharmaceutical company’s stock worth $1,188,000 after buying an additional 2,054 shares in the last quarter. Finally, Isthmus Partners LLC boosted its position in Jazz Pharmaceuticals by 4.9% in the 4th quarter. Isthmus Partners LLC now owns 3,359 shares of the specialty pharmaceutical company’s stock valued at $414,000 after buying an additional 157 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the company. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC reiterated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Morgan Stanley restated an “overweight” rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $190.53.

Jazz Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ JAZZ opened at $136.05 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market cap of $8.26 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The stock’s 50 day simple moving average is $129.17 and its 200 day simple moving average is $120.60.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. This represents a 13.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,736 shares of company stock worth $4,022,825. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.